4
Changes in Ownership
VERTEX PHARMACEUTICALS INC / MA Filed Acc 0000875320-26-000116
EVP, Chief Commercial Officer sold 4,910 shares at an average $487.65 ($2,394,365)
- EVP, Chief Commercial Officer gave up 873 shares (to pay taxes)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
McKechnie Duncan · EVP, Chief Commercial Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-02-24 | Shares withheld for taxes : show line 1 in the form 10b5-1 | −873 | $485.11 | $423,501 | 22,469 | D |
| 2026-02-25 | Sale : show line 2 in the form 10b5-1 | −2,500 | $486.35 | $1,215,875 | 19,969 | D |
| 2026-02-25 | Sale : show line 3 in the form 10b5-1 | −2,410 | $489.00 | $1,178,490 | 17,559 | D |
| Open-market sales · 4,910 sh · avg $487.65 · $2,394,365 | ||||||
Loading xslF345X05/wk-form4_1772149699.xml…